A platform to test breast cancer treatments using patient-derived organ models.
Official title: Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development
Funded at Xylyx Bio, INC. · NIH-11109706 · Data updated 2026-11-12
This study is working on a new way to understand how breast cancer spreads to other parts of the body, using tiny models made from real patient tissues, to help find better treatments that are tailored just for you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xylyx Bio, INC. NIH-funded |
| Lab location | 1 site (Brooklyn, United States) |
| Project start | June 6, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $966,420 |
| NIH project number | 5R44CA287881-02 |
| Project ID | NIH-11109706 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic breast cancer, particularly those whose cancer has spread to the bone, liver, or lung.
✕Less likely to help
Patients with early-stage breast cancer or those whose cancer has not metastasized may not benefit from this research.
What this research studies
This research focuses on developing a novel assay platform that mimics how breast cancer spreads to different organs like bone, liver, and lung. By using patient-derived organoids and human tissue-derived extracellular matrices, the platform aims to create a more accurate model for studying metastatic breast cancer. This approach seeks to improve the prediction of how well potential anti-cancer drugs will work in real patients, ultimately accelerating the development of effective treatments. Patients may benefit from this research as it could lead to more personalized and effective therapies for metastatic breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with metastatic breast cancer.
How similar studies have gone: Other research has shown promise in using organoid models for cancer treatment testing, indicating that this approach could be effective.
Where this research is happening
-
Xylyx Bio, INC.
Brooklyn, United States Active
Researchers
- Principal investigator: O'neill, John David — Xylyx Bio, INC.
- Study coordinator: O'neill, John David
Related research
Other NIH-funded projects on the same topics.
-
Understanding FGFR1-amplified breast cancer to overcome endocrine resistance
This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.
-
Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer
A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.
-
Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active
A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.
-
Acupuncture to ease symptoms for people with metastatic breast cancer
A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.
-
Predicting end-of-life timing to guide better care for metastatic breast cancer
A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.
-
Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer
A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.